Clinical Trials Browser

Blast Crisis, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Acute

NCT02696759 2022-03-16

Gut Microbiome & Gastrointestinal Toxicities as Determinants of Response to Neoadjuvant Chemo for Advanced Breast Cancer

Phase NA Terminated

15 enrolled 6 charts

Breast

Breast Neoplasms, Neoplasms

NCT03956615 2021-12-01

MUM

Phase NA Completed

10 enrolled 6 charts

Plasma cell

Multiple Myeloma

NCT03998189 2021-11-05

Metabolic and Microbial Profiling of Lung Cancer

Phase NA Terminated

1 enrolled 4 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02907918 2021-09-29

PALTAN

Phase 2 Terminated

26 enrolled 8 charts

Breast

Breast Neoplasms

NCT03665155 2021-07-30

First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody

Phase 1/2 Completed

11 enrolled 11 charts

Plasma cell

Multiple Myeloma

NCT00927485 2020-12-16

Use of Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP)

Phase NA Completed

44 enrolled 7 charts

Gastrointestinal

Adenomatous Polyposis Coli

NCT00569309 2018-03-12

Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk Lymphoma

Phase NA Completed

30 enrolled 8 charts

LymphoidPlasma cell

Hodgkin Disease, Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, Follicular, Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell, Lymphoma, Extranodal NK-T-Cell

NCT01048099 2016-01-29

Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer

Phase NA Completed

283 enrolled 8 charts

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT00930930 2015-05-07

Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer

Phase 2 Completed

145 enrolled 10 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT01209520 2015-02-24

Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy

Phase NA Completed

6 enrolled 6 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinogenesis

NCT01227018 2014-07-23

PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer

Phase 2 Terminated

15 enrolled 9 charts

Gastrointestinal

Pancreatic Neoplasms

Clinical Trials

CARDS

PreToxE

A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection

The Safety and Feasibility of Costal Bone Marrow Aspiration During Thoracic Surgery

Evaluating Mitochondrial Dysfunction in Patients With Neurofibromatosis Type 1

Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer

Adipocytokines in Endometrial Cancer

Excite

Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy

Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia

Gut Microbiome & Gastrointestinal Toxicities as Determinants of Response to Neoadjuvant Chemo for Advanced Breast Cancer

MUM

Metabolic and Microbial Profiling of Lung Cancer

PALTAN

First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody

Use of Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP)

Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk Lymphoma

Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer

Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer

Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy

PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer